AZ eyes 25-plus blockbusters

AstraZeneca has doubled down on its target to deliver US$80 billion in total revenue by 2030, with plans to build a portfolio of more than 25 blockbusters by the end of the decade.

The British pharmaceutical giant capped 2025 with fourth-quarter revenues of US$15.5 billion, thanks to the company’s oncology portfolio which contributed US$7 billion to that figure.

During AZ’s Q4 earnings call, CEO Pascal Soriot said, “in 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery.